Table 1.
Clinical Characteristics of Study Population Retested for tTGA
| Initial tTGA Value, U/mL | ||||
|---|---|---|---|---|
| Characteristic | <4 (n=15,398) | 4 ≤ tTGA <40 (n= 120) | ≥40 (n= 33) | P Value |
| Age at initial testing, mean (SD), y | 47.0 (13.8) | 44.1 (12.3) | 41.9 (12.9) | 0.007a |
| Female sex | 8,966 (58.2%) | 68 (56.7%) | 20 (60.6%) | 0.9b |
| Median follow-up interval (IQR), y | 8.9 (7.1–16.4) | 8.2 (6.7–10.1) | 8.2 (7.1–8.9) | 0.004c |
| Initial EMA positive, % | 8 (0.1%)d | 92 (76.7%) | 33 (100%) | <0.001b |
| tTGA at follow-up, U/mL | <0.001b | |||
| <4 | 15,349 (99.7%) | 59 (49.2%) | 8 (24.2%) | |
| 4 ≤ tTGA<40 | 46 (0.3%) | 50 (41.7%) | 10 (30.3%) | |
| ≥ 40 | 3 (0.0%) | 11 (9.2%) | 15 (45.5%) | |
Abbreviations: CeD, celiac disease; EMA, endomysial antibodies; IQR, interquartile range; NA, not applicable; tTGA, tissue transglutaminase antibody.
a
Analysis of variance F-test.
b
χ2 test.
c
Kruskal-Wallis test.
d
Only 112 adults with negative tTGA, whose tTGA values were between 2 and 4 U/mL, were tested for EMA.